Trial Profile
Prediction of the lenalidomide toxicity and its therapeutic efficacy in multiple myeloma patients by measuring its plasma concentration
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 May 2017
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 14 May 2017 Status changed from recruiting to completed.
- 24 May 2016 New trial record